BACKGROUND: Surveillance of children with acute otitis media (AOM) for nasopharyngeal colonization with Streptococcus pneumoniae before, during and after the introduction of 7-valent pneumococcal conjugate vaccine (PCV7) indicated the near-complete elimination of PCV7 strains and the emergence of pneumococcal serotype 19A. METHODS: To determine effects of the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal nasopharyngeal colonization, we obtained nasopharyngeal cultures from 228 children 6 through 23 of age months presenting with a new episode of AOM during 2012 and 2013 and enrolled in an ongoing clinical trial of antimicrobial efficacy. All children had received at least 2 doses of PCV13. The S. pneumoniae isolates were subjected to serotyping and testing for antimicrobial susceptibility. We compared the findings with results obtained in 3 earlier studies. RESULTS: We found nasopharyngeal colonization with S. pneumoniae in 113 (50%) of the children with AOM. PCV7 and PCV13 serotypes accounted for 2% and 12%, respectively, of the pneumococcal isolates. Of the 14 PCV13 isolates, 8 were serotype 19A. Nonvaccine serotypes accounted for 69% of the isolates. Most frequently occurring were subtypes of serotype 15 (23%) and serotype 35B (9%). Overall, 33% of the isolates were penicillin nonsusceptible, a proportion not significantly different from proportions found in our 3 earlier studies (26%, 36% and 37%, respectively). Serotypes 15 and 35B accounted for 51% of penicillin-nonsusceptible isolates. CONCLUSIONS: Expansion of contents of pneumococcal vaccine administered to children is followed by not-fully-predictable changes in nasopharyngeal pneumococcal colonization. Continued surveillance is required to help inform future vaccine development.
BACKGROUND: Surveillance of children with acute otitis media (AOM) for nasopharyngeal colonization with Streptococcus pneumoniae before, during and after the introduction of 7-valent pneumococcal conjugate vaccine (PCV7) indicated the near-complete elimination of PCV7 strains and the emergence of pneumococcal serotype 19A. METHODS: To determine effects of the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal nasopharyngeal colonization, we obtained nasopharyngeal cultures from 228 children 6 through 23 of age months presenting with a new episode of AOM during 2012 and 2013 and enrolled in an ongoing clinical trial of antimicrobial efficacy. All children had received at least 2 doses of PCV13. The S. pneumoniae isolates were subjected to serotyping and testing for antimicrobial susceptibility. We compared the findings with results obtained in 3 earlier studies. RESULTS: We found nasopharyngeal colonization with S. pneumoniae in 113 (50%) of the children with AOM. PCV7 and PCV13 serotypes accounted for 2% and 12%, respectively, of the pneumococcal isolates. Of the 14 PCV13 isolates, 8 were serotype 19A. Nonvaccine serotypes accounted for 69% of the isolates. Most frequently occurring were subtypes of serotype 15 (23%) and serotype 35B (9%). Overall, 33% of the isolates were penicillin nonsusceptible, a proportion not significantly different from proportions found in our 3 earlier studies (26%, 36% and 37%, respectively). Serotypes 15 and 35B accounted for 51% of penicillin-nonsusceptible isolates. CONCLUSIONS: Expansion of contents of pneumococcal vaccine administered to children is followed by not-fully-predictable changes in nasopharyngeal pneumococcal colonization. Continued surveillance is required to help inform future vaccine development.
Authors: Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Nader Shaikh; Ellen R Wald; Diana H Kearney; D Kathleen Colborn; Marcia Kurs-Lasky; Sonika Bhatnagar; Mary Ann Haralam; Lisa M Zoffel; Carly Jenkins; Marcia A Pope; Tracy L Balentine; Karen A Barbadora Journal: N Engl J Med Date: 2011-01-13 Impact factor: 91.245
Authors: M Eldan; E Leibovitz; L Piglansky; S Raiz; J Press; P Yagupsky; A Leiberman; R Dagan Journal: Pediatr Infect Dis J Date: 2000-04 Impact factor: 2.129
Authors: J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä Journal: N Engl J Med Date: 2001-02-08 Impact factor: 91.245
Authors: Peter C Wroe; Grace M Lee; Jonathan A Finkelstein; Stephen I Pelton; William P Hanage; Marc Lipsitch; Abbie E Stevenson; Sheryl L Rifas-Shiman; Ken Kleinman; M Maya Dutta-Linn; Virginia L Hinrichsen; Matthew Lakoma; Susan S Huang Journal: Pediatr Infect Dis J Date: 2012-03 Impact factor: 2.129
Authors: Alejandro Hoberman; David P Greenberg; Jack L Paradise; Howard E Rockette; Judith R Lave; Diana H Kearney; D Kathleen Colborn; Marcia Kurs-Lasky; Mary Ann Haralam; Carol J Byers; Lisa M Zoffel; Irene A Fabian; Beverly S Bernard; Jill D Kerr Journal: JAMA Date: 2003-09-24 Impact factor: 56.272
Authors: Sheldon L Kaplan; William J Barson; Philana Ling Lin; José R Romero; John S Bradley; Tina Q Tan; Jill A Hoffman; Laurence B Givner; Edward O Mason Journal: Pediatr Infect Dis J Date: 2013-03 Impact factor: 2.129
Authors: Jonathan A Finkelstein; Susan S Huang; James Daniel; Sheryl L Rifas-Shiman; Ken Kleinman; Donald Goldmann; Stephen I Pelton; Alfred DeMaria; Richard Platt Journal: Pediatrics Date: 2003-10 Impact factor: 7.124
Authors: Liset Olarte; Sheldon L Kaplan; William J Barson; José R Romero; Philana Ling Lin; Tina Q Tan; Jill A Hoffman; John S Bradley; Laurence B Givner; Edward O Mason; Kristina G Hultén Journal: J Clin Microbiol Date: 2016-11-09 Impact factor: 5.948
Authors: Judith M Martin; Alejandro Hoberman; Nader Shaikh; Timothy Shope; S Onika Bhatnagar; Stan L Block; Mary Ann Haralam; Marcia Kurs-Lasky; Michael Green Journal: Open Forum Infect Dis Date: 2018-02-17 Impact factor: 3.835